SAB Biotherapeutics (SABS) Return on Capital Employed (2021 - 2026)
SAB Biotherapeutics (SABS) posted Return on Capital Employed of 28.98% for Q1 2026, up 0.89% on a QoQ basis from 29.23% in Q4 2025, and up 10527.0% year-over-year from N/an in Q1 2025.
SAB Biotherapeutics (SABS) Return on Capital Employed (2021 - 2026) Analysis & Trends
SAB Biotherapeutics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 28.98% for Q1 2026.
- Quarterly Return on Capital Employed rose 10527.0% year-over-year to 28.98% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 28.98% (up 10527.0% YoY) and the FY2025 annual result came in at 50.04%, up 2646.0% from the prior year.
- Return on Capital Employed was 28.98% for Q1 2026 at SAB Biotherapeutics, up from 29.23% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 28.98% in Q1 2026 and bottomed at 178.37% in Q2 2025.
- A 5-year average of 82.56% and a median of 78.77% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed plunged 10086 bps — and 2026, when it surged 10527 bps.
- SAB Biotherapeutics' Return on Capital Employed stood at 78.77% in 2022, then declined by 7 bps to 84.0% in 2023, then dropped by 25 bps to 104.62% in 2024, then soared by 72 bps to 29.23% in 2025, then gained by 1 bps to 28.98% in 2026.
- Business Quant data shows SABS's Return on Capital Employed at 28.98% in Q1 2026, 29.23% in Q4 2025, and 44.99% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | -28.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.98% |
| Dec 31, 2025 | -29.23% |
| Sep 30, 2025 | -44.99% |
| Jun 30, 2025 | -178.37% |
| Mar 31, 2025 | -134.24% |
| Dec 31, 2024 | -104.62% |
| Sep 30, 2024 | -105.60% |
| Jun 30, 2024 | -77.50% |
| Mar 31, 2024 | -60.65% |
| Dec 31, 2023 | -84.00% |
| Sep 30, 2023 | -119.33% |
| Jun 30, 2023 | -105.35% |
| Mar 31, 2023 | -89.40% |
| Dec 31, 2022 | -78.77% |
| Sep 30, 2022 | -73.09% |
| Jun 30, 2022 | -51.70% |
| Mar 31, 2022 | -37.65% |
| Dec 31, 2021 | -18.45% |